http://www.physorg.com/ en-us Physorg.com internet news portal provides the latest news on science including: Physics, Nanotechnology, Life Sciences, Space Science, Earth Science, Environment, Health and Medicine. Can treatments that reduce risks for cardiovascular disease (CVD) also help combat age-related macular degeneration (AMD), an eye disease that affects millions of Americans? CVD and AMD share some risk factors-such as smoking, high blood pressure, and inflammation-and a recent study found that people who have early-stage AMD are more likely to develop heart disease. This month's Ophthalmology, the journal of the American Academy of Ophthalmology, reports on how two heart disease treatments, low-dose aspirin and statin medications, may impact AMD risk and disease progression. http://www.physorg.com/news178892149.html Medicine & Health Tue, 01 Dec 2009 12:17:06 EST news178892149 A team of scientists from The Forsyth Institute, the University of Connecticut Health Center, the CDC and the Wadsworth Center, have used state-of-the-art technology to elucidate the molecular architecture of Treponema pallidum, the bacterium which causes syphilis. The previously unknown detailed structure of the bacteria can now be shown in three dimensions. This provides the first real image of the pathogen and reveals previously unknown features, which may help fight the spread of syphilis. http://www.physorg.com/news178810220.html Biology Mon, 30 Nov 2009 14:30:02 EST news178810220 A chemical cousin of a drug currently used to treat sepsis dramatically slows the progression of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, in mice. The results offer a bit of good news in efforts to develop a therapy to stop or slow the progression of a disease that generally kills its victims within just a few years. http://www.physorg.com/news175192176.html Medicine & Health Mon, 19 Oct 2009 18:20:03 EST news175192176 Following one of the largest studies ever conducted in Parkinson's disease (PD), researchers at Mount Sinai School of Medicine report today in The New England Journal of Medicine that rasagiline, a drug currently used to treat the symptoms of PD, may also slow the rate of disease progression. http://www.physorg.com/news172946108.html Medicine & Health Wed, 23 Sep 2009 18:00:01 EST news172946108 Patients with advanced non-small cell lung cancer who are given cetuximab (Erbitux) in addition to chemotherapy are 13% less likely to die than those who receive chemotherapy alone, regardless of which chemotherapy drug cocktail is used, new research finds. They also experience slower disease progression and an increased chance of tumour shrinkage. http://www.physorg.com/news172819394.html Medicine & Health Tue, 22 Sep 2009 07:00:01 EST news172819394 With the goal of tailoring cancer interventions for the individual, researchers at the Lombardi Comprehensive Cancer Center at Georgetown have published the results of a prospective study that validates the use of a simple blood test to help doctors more reliably assess treatment effectiveness for patients with metastatic breast cancer. These findings were released on-line today in the Journal of Clinical Oncology. http://www.physorg.com/news172166750.html Medicine & Health Mon, 14 Sep 2009 17:06:30 EST news172166750 A study published in the August 2009 edition of the Journal of Thoracic Oncology found that non-small cell lung cancer (NSCLC) patients could be more accurately staged at diagnosis by taking into account the level of visceral pleura invasion (VPI). VPI is the extension of a tumor beyond the elastic layer of the visceral pleura. http://www.physorg.com/news169895577.html Medicine & Health Wed, 19 Aug 2009 10:13:23 EST news169895577 A new, international study found that the combination of two drugs delays disease progression for patients with advanced non-small cell lung cancer (NSCLC). Results from the Phase III "ATLAS" trial were presented today by Dr. Vincent Miller of Memorial Sloan-Kettering Cancer Center (MSKCC) at the American Society of Clinical Oncology Annual Meeting. http://www.physorg.com/news162994985.html Medicine & Health Sun, 31 May 2009 13:23:30 EST news162994985 Every tumor, starting from a size of a few millimeters, depends on a supply of nutrients and oxygen. Therefore, using special growth factors, it induces vascular wall cells of neighboring blood vessels to sprout new capillaries in order to get connected to the blood circulation. http://www.physorg.com/news156076809.html Medicine & Health Thu, 12 Mar 2009 11:40:40 EST news156076809 NovoCure Ltd. presented results yesterday evaluating the Novo-TTF device in vitro and in a pilot clinical trial that showed the device enhanced the efficacy of standard chemotherapy (temozolomide) treatment in newly-diagnosed glioblastoma multiforme (GBM) patients. When used in combination with standard chemotherapy, the Novo-TTF, a non-invasive medical device that uses low intensity alternating electric fields to destroy cancer cells, enhanced the anti-tumor effects of standard chemotherapy, thus prolonging time to disease progression and extending survival. http://www.physorg.com/news146746552.html Medicine & Health Mon, 24 Nov 2008 10:55:52 EST news146746552 A new study published in Journal of Neuroimaging shows that MRI scans used on multiple sclerosis (MS) patients to determine if the disease has affected gray matter in the brain can identify those at-risk for progression of disability. http://www.physorg.com/news145122340.html Medicine & Health Wed, 05 Nov 2008 15:45:40 EST news145122340